Menkes Disease Market is segmented By Treatment Type (Copper Replacement Therapy, Pharmacological Interventions, Supportive Care), By Diagnosis (Genet....
Market Size in USD
CAGR6.6%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 6.6% |
Market Concentration | High |
Major Players | Fortress Biotech, Inc., Teva Pharmaceutical Industries Ltd., Amerigen Pharmaceuticals Limited, Mylan N.V., Bausch Health Companies Inc. |
The Global Menkes Disease Market is estimated to be valued at USD 165.1 million in 2024 and is expected to reach USD 259.2 million by 2031, growing at a compound annual growth rate (CAGR) of 6.65% from 2024 to 2031. The market is expected to exhibit steady growth over the forecast period owing to increase in research and development activities for developing effective treatment options and rising prevalence of the genetic disorder worldwide.
The Menkes Disease market is anticipated to be driven by rising awareness about the disease and its treatment. Advancements in gene therapy and development of newer treatment options are projected to offer lucrative opportunities in the coming years. However, high cost of treatment and lack of approved treatment options are major challenges for the market. Nevertheless, favorable government initiatives and focus on rare disease research are expected to create new avenues for the key players operating in the market.